Associated Papers
Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population.
Arun AS et al.
The Pharmacogenomics Journal, 2025
40044654 (PubMed )
Supplement: 41397_2025_364_MOESM3_ESM.xlsx › Sheet1
Cancer-driving mutations are enriched in genic regions intolerant to germline variation.
Vitsios D et al.
Science Advances, 2022
36026442 (PubMed )
Supplement: sciadv.abo6371_tables_s1_to_s13.zip › sciadv.abo6371_tables_s1_to_s13.xlsx › S2
Exome sequencing identifies somatic mutations in novel driver genes in non-small cell lung cancer.
Zhang M et al.
Aging, 2020
32629428 (PubMed )
Supplement: aging-12-103500-s002..xlsx › Sheet1
Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers.
Ahn JW et al.
Genome Medicine, 2014
Select a paper to view details